358 results about "Brain traumas" patented technology

The invention discloses a mild traumatic brain injury image evaluation system based on deep learning, and relates to the technical field of medical imaging, and the system comprises a data source module which is used for obtaining head magnetic resonance imaging data as an input data source; the preprocessing module is used for carrying out de-noising processing and image registration on the skull magnetic resonance imaging data to realize standardized preprocessing; and the feature extraction module is used for extracting a local feature map from the multi-dimensional image data by constructing a multilayer convolutional neural network, and identifying a subcortical structure change and damage suspicious region. According to the mild traumatic brain injury image evaluation system based on deep learning provided by the invention, a standardized evaluation report automatically generated by the system not only integrates clinical information of a patient, but also provides detailed injury types, severity and follow-up visit suggestions, so that the efficiency and reliability of clinical decision making are greatly improved; and powerful support is provided for formulating an individualized diagnosis and treatment scheme.

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

Disclosed are methods of treating traumatic brain injury in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention relates to the technical field of extracranial strike testing, in particular to digitally-controlled extracranial strike construction equipment of a traumatic brain injury model. Comprising a test platform, a sliding rail installed on the test platform and arranged in the length direction of the test platform, an animal fixing platform slidably connected with the test platform through the sliding rail, an impact structure arranged on one side of the test platform and a driving structure used for driving the animal fixing platform to move towards the impact structure. The impact structure is fixedly connected to the test platform, the output end of the impact structure faces the animal fixing platform, an experimental animal is installed on the animal fixing platform, the driving structure drives the animal fixing platform to enable the experimental animal to actively impact, and the impact structure enables the experimental animal to impact a fixed acting point at a certain initial speed. The system is more in line with the injury mechanism of a patient with clinical actual craniocerebral trauma, and a tester can accurately control and monitor parameters according to the moving speed and the moving distance of the animal fixing platform.

The invention belongs to the technical field of molecular biology, and particularly provides a biomarker for traumatic brain injury detection, the biomarker comprises NSE and GFAP, and preferably further comprises at least one of S100B, UCH-L1, P-tau and IL-6. On the basis of the biomarker, a reagent card, a kit, a system and other traumatic brain injury assessment products are provided, a rapid and non-invasive assessment alternative scheme is provided for traumatic brain injury, and assistance is provided for early intervention treatment. The radiation exposure risk of the patient is reduced, the diagnosis process is accelerated, and the illness state can be evaluated more comprehensively. Biomarkers are used in combination with the clinical severity of TBI and therapeutic care pathways, enabling better identification and hierarchical management of mild and severe patients. The biomarkers of the invention can provide extremely significant and highly credible test results for specific patient populations requiring admission treatment or at different clinical severity.

The invention belongs to the technical field of damage assessment, and particularly relates to a construction method of a rat traumatic brain injury model caused by explosive shock waves. By protecting other important visceral organs except the brain, interference of damage of visceral organs such as the lung to brain injury is avoided, the overall function stability of the body is maintained, the caused brain injury can more truly reflect the characteristics of explosive traumatic brain injury, and the credibility and repeatability of experimental data are improved. The construction method simulates loading of explosion shock wave parameters in a real environment, constructs an animal traumatic brain injury model through live ammunition explosion, is closer to an actual combat environment, and can truly reflect physical parameters related to explosion and a complex action process generated by interaction of the physical parameters. And a support is provided for developing molecular mechanisms of explosive traumatic brain injury, clinical diagnosis, screening of therapeutic drugs and the like.

Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.

A method and device for reducing the damaging effects of a blast or concussive event includes applying pressure to at least one jugular vein to reduce the egress of blood from the cranial cavity during the incidence of the concussive event. Reducing blood out flow from the cranial cavity increases intracranial pressure of the cerebrospinal fluid to reduce the risk of traumatic brain injury and injuries to the spinal column. Reducing blood out flow further increases the intracranial pressure, and thereby increases the pressure of the cochlear fluid, the vitreous humor and the cerebrospinal fluid to thereby reduce the risk of injury to the inner ear, internal structure of the eye and of the spinal column. In addition, increasing intracranial pressure reduces the likelihood of brain injury and any associated loss of olfactory function.

The present invention relates generally to compositions and methods useful for treating brain injuries such as stroke, optic neuropathy, traumatic brain injury, and cerebral palsy. The methods comprise administering to a subject HMC obtained by in vitro differentiation of pluripotent stem cells and / or extracellular vesicles (EV) derived from these HMCs (HMC-EV).

The present invention relates to assays, methods, and kits to assess traumatic brain injury (TBI) in a subject. The present invention also relates to ultrasensitive assays for GFAP, tau, CKBB, IL-1β, IL-2, IL-6, IL-10, IL-22, IP-10, TNFα, TSLP, NFL, and / or NFH.

The invention provides a response liposome for treating traumatic brain injury by targeting a blood-brain barrier loaded drug and a preparation method of the response liposome, and belongs to the field of traumatic brain injury treatment.The response liposome is prepared by preparing TfR-T12 target peptide firstly, then preparing nano-particles with hydrophobic molecular drugs wrapped inside, and finally preparing the TfR-T12 target peptide with the hydrophobic molecular drugs wrapped inside. And finally, preparing the response liposome for treating traumatic brain injury by the targeted blood-brain barrier loaded medicine. According to the application, the TfR-T12 target peptide which is highly expressed in cerebral cortex microvessels and can help a nano-drug to pass through a blood brain barrier through endocytosis is prepared as a target spot, meanwhile, the liposome is subjected to polypeptide modification, and the self-assembly driving force of the nano-particles is improved through process control; the outer surface of the response lipidosome is a target peptide, and the response lipidosome is internally coated with a nano-drug; the liposome can repair the blood brain barrier after injury, improve the blood flow of the brain, improve the drainage of the colloidal lymphatic system, improve the motor and cognitive functions of mice after injury, and reduce the dosage of drugs and various possible side effects caused by the drug dosage.

The present disclosure generally relates to methods and formulations for treating central nervous system (CNS) disorders. The present disclosure involves intranasal delivery of at least one antioxidant compound, allowing for effective treatment of a central nervous system disorder such as traumatic brain injury or stroke.

The invention discloses a rapid detection method for traumatic brain injury by fusing genetic engineering and quantum dots, and relates to the technical field of traumatic brain injury detection. The method comprises the following steps: acquiring a suspected patient biological sample, extracting biomolecule components, and comparing the biomolecule components with a healthy population biomolecule database to obtain related differential expression molecules. A specifically recognizable recombinant antibody is constructed by genetic engineering, and is connected with a quantum dot through a coupling reaction to prepare a detection probe. The probe and a biological sample are mixed and reacted, and the intensity of a fluorescence signal generated by combination is collected by a fluorescence detection device. A standardized signal value is obtained through signal processing algorithm noise reduction and feature extraction, and a preliminary detection result is determined by combining a bioinformatics database evaluation sample. And finally, according to the differential expression molecule, the standardized signal value and the preliminary result, analyzing a data change trend in a preset time window by using a multivariable statistical model, and generating a diagnosis report. According to the method, various technologies are fused, and a new path is provided for traumatic brain injury detection.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention belongs to the field of biological materials, and particularly relates to a multifunctional DNA nanometer material, a preparation method and application of the multifunctional DNA nanometer material in treatment of traumatic brain injury secondary encephaledema. The multifunctional DNA nano material comprises a plurality of deoxyribozyme (DNAzyme) targeting C1q mRNA (messenger Ribonucleic Acid) and a repeating unit which is integrally connected with G-quadruplex / Hemin in series, wherein the G-quadruplex / Hemin is labeled by streptavidin SA and biotin and is used for scavenging free radicals. The DNAzyme for silencing the C1q gene of the mouse is designed on the basis of a bioinformatics method, and the C1q gene overexpressed in an inflammation model can be knocked down to an approximate normal level. The RCA technology mediated self-assembled nano material SA-B / H has excellent enzyme mimetic activity, can effectively remove free radicals such as H2O2 and O2 <.->, and has the potential of in-vivo oxidation resistance. In-vitro experiments prove that SA-B / H can effectively relieve high-level oxidative stress of cells caused by H2O2 stimulation.

The invention belongs to the technical field of biological medicines, and particularly relates to an MXene nano material with high SOD (superoxide dismutase) enzyme activity as well as a preparation method and application thereof. The MXene nano material with high SOD (superoxide dismutase) enzyme activity, disclosed by the invention, comprises Mo2C MXene and a metal atom anchored on the Mo2C MXene. The MXene nano material with high SOD enzyme activity has the beneficial effects that the MXene nano material with high SOD enzyme activity has relatively high SOD enzyme activity and a strong ROS removal characteristic, and oxidative stress injury can be relieved; the compound has the effect of treating ROS related diseases such as traumatic brain injury (TBI), Parkinson's syndrome (PD) and chronic obstructive pulmonary disease.

The present invention generally relates to compositions and methods useful for treating a brain injury such as stroke, optic neuropathy, traumatic brain injury, and cerebral palsy. The methods include administering HMCs obtained by in vitro differentiation of pluripotent stem cells and / or extracellular vesicles (EVs) derived from such HMCs (HMC-EVs) into a subject.

The invention provides multifunctional bionic hydrogel as well as preparation and application thereof in traumatic brain injury treatment, and belongs to the field of biomedical materials. The preparation method comprises the following steps: combining polydopamine modified hemoglobin nanoparticles with curcumin-based carbon quantum dots with anti-inflammatory activity, and embedding into bionic hyaluronic acid-collagen double-network hydrogel, so as to prepare the multifunctional bionic hydrogel. The hydrogel can effectively relieve neuron hypoxia, reduce apoptosis, promote the polarity of microglial cells to be converted into anti-inflammatory phenotype, and significantly down-regulate the expression of S100A8, thereby inhibiting pathological neural immune crosstalk. In a traumatic brain injury model, hydrogel implantation improves the pathological microenvironment, enhances endogenous nerve regeneration, and ultimately results in significant neurological function and cognitive recovery. The multifunctional bionic hydrogel prepared by the invention has a good application prospect in preparation of materials for preventing and / or treating traumatic brain injury.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The invention belongs to the technical field of medical instruments, and discloses a surgical instrument for building a traumatic brain injury mouse model.The surgical instrument comprises a tube blade, a limiter, a holding piece and a vacuum device, the tube blade is used for rotationally cutting into brain tissue of a mouse, the limiter is movably installed on the tube blade in the axial direction of the tube blade, and the vacuum device is arranged on the holding piece; the limiting device is used for abutting against the skull of the mouse, the holding piece is provided with an airflow channel, one end of the holding piece is connected with the pipe blade, one end of the airflow channel is communicated with the pipe blade, and the vacuum device is connected to the other end of the holding piece and connected with the other end of the airflow channel. According to the surgical instrument for building the traumatic brain injury mouse model, the problems that an injury area is uncontrollable and a focus area is difficult to quantify and unify in the current traumatic brain injury mouse model building process can be solved, so that the success rate and efficiency of model building are improved to the maximum extent.

A system for evaluating cognitive function is disclosed herein. In some embodiments, the system includes a computing device with a processor; and a visual display device. The computing device is operatively coupled to said visual display device, said computing device being programmed to generate and display a cognitive test on said visual display device for assessing a mental ability of said patient, said cognitive test comprising a plurality of different images for said patient to identify, said cognitive test assessing the mental ability of said patient that is suspected of having sustained a traumatic brain injury (TBI). Also, in some embodiments, the system is in a form of a telemedicine system that includes a local control system disposed at a first location and a central control system disposed at a remote site.

The invention discloses a bionic bacterial outer membrane nano-particle for drug delivery. The bionic bacterial outer membrane nano-particle is characterized by comprising low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out, and low-toxicity outer membrane vesicles extracted from escherichia coli with msbB genes knocked out; the medicine carrying liposome is prepared from phosphatidylcholine, cholesterol and DSPE-PEG2000 (Distearoyl Phosphatidylcholine-Polyethylene Glycol 2000) according to a preset mass ratio; the low-toxicity outer membrane vesicles and the drug-loaded liposome are subjected to ultrasonic assistance and 100nm filter membrane extrusion to obtain bionic bacterial outer membrane nanoparticles, the average particle size of the bionic bacterial outer membrane nanoparticles is about 100nm, and the encapsulation efficiency exceeds 85%. The BM-NPs system disclosed by the invention can load small molecule compounds, proteins, nucleic acids and gene therapy vectors, and is suitable for various central nervous system diseases such as spinal cord injury, cerebral apoplexy, traumatic brain injury, ischemia-reperfusion injury and the like.

This paper presents a medical device for treating traumatic brain injury and cerebral thrombosis through electroacupuncture. The device includes a 6-DOF (degree of freedom) mechanical arm, a multifunctional tool tip, an MRI helmet suitable for acupuncture, and magnetic resonance imaging (MRI). The acupuncture robot can insert needles and automatically manipulate specific needles by rotating or vibrating them within a specific frequency range, and can enhance the effect by applying electrical stimulation.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present inventive concept provides methods of determining whether a subject has cortical or cerebral visual impairment (CVI) as well as determining whether the subject has a traumatic brain injury thereby allowing treatment for these conditions. The present inventive concept also provides a standardized method for assessing pediatric or adolescent visual acuity.

The present invention relates to compounds, compositions and methods for deinhibiting a RE1 silencing transcription factor (REST) target gene. In particular, disclosed is a peptide having the sequences TEDLEPPEPPLPKEN (SEQ ID NO: 1) and EDLEPPEPPLPK (SEQ ID NO: 15) or a reverse sequence (reverse inversion, RI) consisting of D-amino acids nekplppeppeldet (SEQ ID NO: 16) and kplppeppelde (SEQ ID NO: 17), for use in the inhibition of REST activity. The peptides can be used for treating, preventing or alleviating diseases such as traumatic brain injury, epilepsy, dementia, Huntington's disease (HD), chronic pain, brain cancer (including glioblastoma multiforme), pancreatic cancer, diabetes and peripheral nerve injury.

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of IFNAR1 RNA in a cell or an animal, and in certain instances, reducing the amount of IFNAR1 protein in a cell or animal. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to treat diseases and conditions associated with neuroinflammation, including Aicardi-Goutieres Syndrome, stroke, neuropsychiatric systemic lupus erythematosus, neuroinflammation following traumatic brain injury, neuro-autoimmune disorders, Alzheimer's disease, post-operative delirium and cognitive decline, cranial radiation-induced cognitive decline, viral infection-induced cognitive decline, neuromyelitis optica, and ataxia telangiectasia.